Supernus Pharmaceuticals reported $224.63M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbott ABT:US USD 2.69B 65M
Aerie Pharmaceuticals AERI:US USD 33.88M 5.73M
Ani Pharmaceuticals ANIP:US USD 30.08M 1.88M
Aurora Cannabis Inc ACB:CN CAD 45.04M 5.32M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Canopy Growth Corp WEED:CN CAD 125.74M 27.65M
Cara Therapeutics CARA:US USD 6.88M 658K
Corcept Therapeutics CORT:US USD 35.16M 2.65M
Eisai 4523:JP JPY 88.08B 4.22B
Eli Lilly And LLY:US USD 1.61B 10.9M
Endo International Ordinary Shares ENDP:US USD 192.46M 10.92M
Horizon Pharma HZNP:US USD 397.56M 658K
Lannett LCI:US USD 16.7M 9.06M
Marinus Pharmaceuticals MRNS:US USD 13.39M 3.67M
Pacira Pharmaceuticals PCRX:US USD 61.28M 3.72M
Perrigo Ordinary Shares PRGO:US USD 281M 57.1M
Pfizer PFE:US USD 3.54B 345M
Revance Therapeutics RVNC:US USD 64.09M 17.91M
Supernus Pharmaceuticals SUPN:US USD 224.63M 124.15M
Teva Pharmaceutical Industries TEVA:US USD 777M 72M
United Therapeutics UTHR:US USD 98.4M 43.1M
Xeris Pharmaceuticals Inc XERS:US USD 34.49M 1.51M